Stockscreener 앱 받기
625.65
2.37%
-15.21
시간 외 거래:
625.80
0.15
+0.02%
전일 마감가:
$640.86
열려 있는:
$655
하루 거래량:
14.08M
Relative Volume:
3.37
시가총액:
$592.95B
수익:
$53.26B
순이익/손실:
$13.80B
주가수익비율:
40.89
EPS:
15.3
순현금흐름:
$-50.20M
1주 성능:
-17.93%
1개월 성능:
-19.55%
6개월 성능:
-28.77%
1년 성능:
-25.99%
1일 변동 폭
$623.78
$656.18
1주일 범위
$623.78
$774.48
52주 변동 폭
$623.78
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Lilly launches "The Court Is Hers™" to help more girls get in the game - Eli Lilly and Company
Eli Lilly (LLY) Partners With Senderra For Innovative Digital Patient Care Solution - uk.finance.yahoo.com
Eli Lilly’s Stock Dips Amid Weight-Loss Pill Setback - TipRanks
Earnings Beat: Eli Lilly and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $825 to $1,190 - 富途牛牛
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water - Benzinga
IonQ, Eli Lilly, Monster, Crocs, Kratos Trending by Analysts - TipRanks
BMO Raises Eli Lilly (LLY) Price Target, Keeps Outperform Rating - Insider Monkey
Director’s Bold Move: Major Investment in Eli Lilly & Co Stock - TipRanks
Why Novo Nordisk Stock Flew Higher on Friday - The Motley Fool
Lilly Shares Slide Following Weight Loss Pill Trial Results - InkFreeNews.com
Celltrion in talks to buy Eli Lilly plant in US for $504 million - KED Global
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst - Benzinga
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity? - MSN
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data - Barchart.com
Eli Lilly Stock Collapsed On Its Shocking Obesity Flop — Is It Now A Sell? - Investor's Business Daily
Eli Lilly stock rating reiterated at Overweight by JPMorgan - Investing.com South Africa
Eli Lilly Stock (LLY) Continues to Sink as Enthusiasm for Obesity Pill Fades - TipRanks
Eli Lilly: 50% Upside For LLY Stock? - Forbes
Eli Lilly stock price target lowered to $895 by UBS on orfo data concerns - Investing.com
Eli Lilly defends itself after disappointing obesity data: “It’s tough to compare" - medwatch.com
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried? - The Motley Fool
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Call Transcript - Insider Monkey
Novo Nordisk execs respond to rival's tablet data: "We can make a really great launch in the US” - medwatch.com
Eli Lilly’s once daily oral pill shows major weight loss in trials: Is this easier to use than taking a shot? - The Indian Express
Morgan Stanley reiterates Overweight rating on Eli Lilly stock, citing GLP-1 growth - Investing.com
Eli Lilly price target lowered to $895 from $1,050 at UBS - TipRanks
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) - StreetInsider
Morgan Stanley trims Eli Lilly price target, calls selloff ‘overdone’ - TipRanks
Eli Lilly & Co: Strong Buy Rating Backed by Robust Performance and Growth Prospects - TipRanks
Eli Lilly Earnings: Weak Orforglipron Obesity Data Weighs Down a Strong Quarter - Morningstar
Eli Lilly sees challenges in the US: Compounders are rampant while CVS prefers Novo Nordisk - medwatch.com
Eli Lilly and Company (NYSE: LLY) | Stock Quote, Chart, Outlook - AskTraders.com
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Eli Lilly and Co (LLY) Q2 2025 Earnings Call Highlights: Record - GuruFocus
Eli Lilly, a U.S. pharmaceutical company that has led the world's largest anti-obesity drug market - 매일경제
Eli Lilly's orforglipron achieves weight loss goal but stock drops 14%CHOSUNBIZ - Chosunbiz
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound - Stocktwits
Eli Lilly (LLY) Stock: Drops 14% Despite 38% Revenue Growth Led by Zepbound and Mounjaro - CoinCentral
Chugai Highlights Eli Lilly’s Positive Phase 3 Results for Orforglipron - TipRanks
Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In (NYSE:LLY) - Seeking Alpha
Eli Lilly could get $100M in tax credits for Wisconsin expansion - Finance & Commerce
Pill-version of popular weight loss drugs could be available, Eli Lilly officials say - WUSA9
Lilly's beat-and-raise quarter can't escape orforglipron's shadow - FirstWord Pharma
Earnings live: Eli Lilly stock slides, Pinterest sells off, Block gains after hours - ca.finance.yahoo.com
Earnings live: Eli Lilly stock slides, Pinterest sells off, Expedia and Block gain after hours - uk.finance.yahoo.com
Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat - Bloomberg.com
Closing a zombie biotech, and Lilly’s disappointing obesity readout - statnews.com
Eli Lilly stock sell-off ‘overdone’ as weight-loss pill remains ‘commercially viable’ - Invezz
Eli Lilly weight loss pill shows promise, but not as strong as injectables - AOL.com
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today - Yahoo Finance
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
0.41%
자본화:
|
볼륨(24시간):